摘要
目的:了解米氮平合并重复经颅磁刺激对卒中后抑郁的疗效。方法:将60例卒中后抑郁患者随机分为治疗组和对照组,2组患者均常规给予卒中治疗,治疗组在使用米氮平基础上合并重复经颅磁刺激,对照组仅使用米氮平治疗,分别于治疗前及1、2、4周使用汉密尔顿抑郁量表(HAMD)评价临床疗效,并与治疗前及治疗后使用美国国立研究院脑卒中评定量表(NIHSS)及日常生活能力量表(ADL)评价康复效果。结果:2组患者治疗前及治疗后HAMD、NIHSS评分明显下降,ADL评分明显上升,统计学处理有显著性差异(P<0.05),而合并重复经颅磁刺激组在第1周时HADM评分与对照组比较统计学处理有显著性差异(P<0.05)。结论:抗抑郁药在合并重复经颅磁刺激治疗能更快改善卒中后抑郁患者的临床症状并增加抗抑郁的临床疗效。
Objective：To explore the efficacy of mirtazapine merge rTMS to treatment of post -stroke depression.Methods：Sixty patients with post -stroke depression were randomly divided into treatment and control group.All patients were routinely given to the treatment of stroke.Treatment group on the basis of the use of mirtazapine combined rTMS,and control group only use mirtazapine.To evaluate the clinical efficacy using the Hamilton Depression Rating Scale（HAMD） when before and after 1、2 and 4 weeks treatment,respectively. Meanwhile,using the U.S.National Institutes of stroke Rating Scale（NIHSS） and daily living scale（ADL） to evaluate the rehabilitation when before and after treatment.Results：Significant difference were found,with HAMD and NIHSS score decreased and ADL score increased significantly,between two groups of patients when before and after treatment（P0.05）.The significant difference were found with the HADM rating when first week trement between rTMS and control group（P0.05）.Conclusion：Antidepressants in the combined rTMS therapy may improve the clinical symptoms of patients with post-stroke depression faster and increase the clinical efficacy of antidepressant.
出处
《中国伤残医学》
2013年第6期48-50,共3页
Chinese Journal of Trauma and Disability Medicine
